Wilmington PharmaTech Expands U.S. API Manufacturing Capacity
The company will add new reactor suites to its Delaware campus, increasing its API reactor capacity by more than double and enabling the company to meet new demand for high-quality domestic manufacturing.
U.S.-based research, development, and manufacturing organization (CRDMO), Wilmington PharmaTech, is expanding its Delaware campus to more than double the current API reactor capacity. The USD 50 million expansion, which was announced in a March 23, 2026 press release, will support the growing demand for high-quality, U.S.-based manufacturing (1).
Through the expansion, the company will add two new 10,000-liter reactor suites to the Delaware campus, significantly increasing its commercial-scale manufacturing capabilities and enhancing its ability to support large-scale production of small-molecule APIs and peptides. Wilmington expects the new suites to come online during the third quarter of 2027, and once the expansion is completed, it expects that its workforce will approximately double in size (1).
“Over the past decade, Wilmington has been among the few companies to actively invest in CGMP API manufacturing capacity in the U.S., including the recent addition of two new commercial-scale high-potency API suites,” said Hui-Yin “Harry” Li, Ph.D., Founder and CEO of Wilmington PharmaTech, in the company press release (1). “This expansion builds on more than 20 years of CGMP manufacturing expertise and further strengthens our high-output scientific engine in solving complex chemistry challenges at scale.”
“Curewell Capital is proud to support Wilmington in expanding high-quality commercial API production in the U.S.,” added Kent Payne, Ph.D., Operating Partner at Curewell Capital and Managing Director at Wilmington PharmaTech, in the press release (1). “We believe Wilmington is uniquely positioned to serve biopharmaceutical innovators with reliable, scalable domestic production, helping to bolster supply chain resilience and ensure patients have access to critical therapies.”
This latest investment represents the next phase of Wilmington’s multi-year strategy to expand domestic API manufacturing capacity, building upon the company’s recent addition of dedicated suites for the manufacture of highly potent API (HPAPI). In addition to these suites, the company has a dedicated area for antibody-drug conjugates and greenfield sites reserved for future expansion into biologics production.
In October 2025, the company secured investment from Curewell Capital for the provision of growth capital to allow for the expansion of manufacturing and technology capabilities. “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies, and we are committed to further expanding our capabilities and capacity to better serve our global biopharmaceutical partners,” remarked Li, in a press release about the Curewell’s significant investment in the company (2).
“We are thrilled to partner with Dr. Li and his outstanding team, who have built an exceptional organization with deep scientific expertise and a strong reputation for excellence within the pharma science community,” said Michael Dal Bello, Partner at Curewell Capital, in the press release (2). “Our investment will help WPT accelerate its next phase of growth amid strong market demand for specialized development capabilities and dependable, high-quality manufacturing capacity in the U.S.”
References
Wilmington PharmaTech. Wilmington PharmaTech Launches $50 Million Expansion to Double U.S. Small-Molecule API Manufacturing Capacity in Delaware. Press Release, March 23, 2026.
Wilmington PharmaTech. Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital. Press Release, Oct. 21, 2025.